Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Trastuzumab has changed the standard of care for MBC patients who overexpress the HER2-receptor protein. In heavily pretreated patients who overexpress HER2, trastuzumab produces objective ...